Russia’s experimental cancer vaccine, Enteromix, has successfully completed preclinical trials, showing a 60–80% tumor reduction and improved survival in tested animals. Initially developed for colorectal cancer, researchers are also exploring versions for glioblastoma, melanoma, and rare ocular melanoma. While some reports claim 100% effectiveness, verification remains pending. The vaccine is “ready for use” pending government approval, but no timeline for human trials or widespread availability has been announced. Experts see it as a potential breakthrough in cancer treatment.